Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats-Reference-Cited by-同舟云学术

Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats

Published:2012-11-02 Issue:8 Volume:28 Page:1072-1079
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord.

Author:

Papathanou Maria¹²,van der Laan Rika¹,Jenner Peter²,Rose Sarah²,McCreary Andrew C.¹

Affiliation:

1. Abbott Healthcare Products B.V.; Weesp the Netherlands

2. Neurodegenerative Diseases Research Group; Institute of Pharmaceutical Science; School of Biomedical Sciences; King's College London; London United Kingdom

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/mds.25218/fullpdf

Reference55 articles.

1. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications;Olanow;Lancet Neurol,2006

2. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease;Olanow;Nat Clin Pract Neurol,2006

3. The concept of continuous dopaminergic stimulation: what we should consider when starting Parkinson's disease treatment;Stocchi;Neurodegener Dis,2010

4. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease;Nyholm;Neurology,2005

5. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients;Shoulson;Neurology,1975

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expanding the repertoire of L-DOPA’s actions: A comprehensive review of its functional neurochemistry;Progress in Neurobiology;2017-04

2. The novel 5-HT1A, receptor agonist, NLX-112 reduces L-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements;NEUROPHARMACOLOGY;2016

3. NLX-112, a novel 5-HT 1A receptor agonist for the treatment of l -DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat;Experimental Neurology;2015-09

4. Ranitidine reduced levodopa-induced dyskinesia by remodeling neurochemical changes in hemiparkinsonian model of rats;Neuropsychiatric Disease and Treatment;2015-05

5. Experimental reappraisal of continuous dopaminergic stimulation against L-dopa-induced dyskinesia;Movement Disorders;2012-11-09